Clinical Research Progress of Iparomlimab Plus Tuvonralimab in the Treatment of Malignant Tumors

Iparomlimab and Tuvonralimab (QL1706) is the first bifunctional antibody combination in the world to simultaneously target programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). By concurrently blocking the PD-1/PD-L1 and CTLA-4/B7 signaling pathways, it is able to enhance anti-tumor immune activation and help maintain a more durable immune response. On September 26, 2024, QL1706 received its first approval in China for the treatment of recurrent or metastatic cervical cancer after failure of platinum-based chemotherapy. In addition to cervical cancer, clinical studies have also shown encouraging anti-tumor activity in several other solid tumors, including lung cancer, nasopharyngeal carcinoma, and hepatocellular carcinoma. In terms of safety, most treatment-emergent adverse events (TEAEs) reported with QL1706 have been mild to moderate, while the incidence of high-grade immune-related adverse events (irAEs) has remained relatively low. This review summarizes the molecular design, mechanisms of action, and key clinical advances of QL1706, with the aim of providing a reference for its more rational use in clinical practice.